NVTA - Earnings call transcript Q4 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by. And welcome to Invitae's Fourth Quarter and Year End 2019 Financial Results Conference Call [Operator Instructions].

I would now like to hand the conference over to Laura D'Angelo, Head of Investor Relations. Thank you. Please go ahead.

Laura D'Angelo

good and operator, you, afternoon, everyone. Thank for year end you joining us and quarter fourth our XXXX for Thank earnings call.

Joining our our George, CFO; Katherine us our CEO; Commercial Chief Shelly Sean today Officer. Guyer, Stueland, our Lee COO; Medical Chief Bandekgey, Nussbaum, Bob Officer; and are our

to commentary our As as financial to you well call, on release press as we conference listen our available, and the results, quarter. you encourage metrics today's have which includes

opportunities, various future remarks the meaning products, like Safe pipeline call in plans reimbursement Litigation I'd we future of for operating and of our that strategy, product our forward-looking Act. plans the timing focus the Private of on historical, remind Before constitute our results, the our we operations, to this demand statements our that market you services, to our that and including begin, of make those services, within financial infrastructure the our we not and and are investment integrate prospects, businesses provisions Reform business about thereof, and acquire, our and manage Harbor Securities and

our actual to It and our for materially predict results guidance. from could our accurately therefore, differ services demand is difficult

additional Factors only to in for among quarter on speak restructurings expectations. additional on XXXX, date forward-looking XX-Q we differ current section our for that the business information you ended from guidance or refer These other acquisitions, September could legal as the Risk titled actual hereof. company Our materially the performance particular don't future our factors cause results to statements assumes, to investments, that XX, things, conclude any settlements. We

and loss per in in press through Accepted cash States, period, operating to these and you the in financial as non-GAAP research net review Generally the expenses, revenue, and the release monitor several burn. marketing development, to GAAP, including non-GAAP non-GAAP Slide supplement and prepared we deck. this our statements available well Accounting share encourage consolidated accordance in include and measures administrative, are as earnings of GAAP XX In consider loss and To the cost and and net general United measures. We which of with XX or our reconciliations, selling Principles

I that, will turn to over With Sean. the call

Sean George

by in margin industry on years mission globe. in is of on costs the to maximize models, healthcare medical a that used transform of genetics a test way served continues our high our from by outcomes and mainstream to business genetic information used around individuals XX where niche billions for is to confidence to basis, one market where medical the bring to one information test the to genetic indication sparingly genome the genetic testing lower as indication by utility the utility improve the broadly the is care, grow

be routine able We posted XXXX to explosive as well of driven as with who as as momentum to believe be the year growth we in of another medical course increase business, will by landscape individuals to we the number information our year model, care. and the breakout of the we're continue accelerating a genetic changes a access will seeing

see every to and our across into and for the us more ones, demand afflict franchises continued the ascribed screening our areas, with continue that and diagnostic week We diseases more information disease testing services growth the our all future. genetic grow and to foreseeable seemingly loved and we being

business focused now Our to continues for network partnerships biopharma on accelerate.

faster. we sooner networks well contracts, and diagnose systems, of enroll faster partnerships. to to we can health as remove biopharma the partners, patients added to therapies physician to ever, beginning bring provide our more and Since national than and QX, drug with information as trials researchers barriers Together and developers XX hospital market

the our deepening and network platform this broadening within. in invest capabilities to of continue will We

of with this volume modest around commercial effort. To-date from XX% States, has come United the Invitae's outside the

are and ever information also investment, from few the international our economies more convinced being increased globe millions use than of the individuals modern Now genetic that benefit into leadership, around put their with months can for everyday a we to hundreds our of health. current

benefit us addition, longevity. of able understand their the or daily risk to about to general answer or direct thinking continued have understand will questions in channel in family, In for to today our investment of use perhaps not meet the simply specialists wellness, information, from individuals past, afflicting when wanting in information this genetic what's been interested allow health, need many the looking to starting the that the at to whether disease or from one,

annual will to the and over quarterly Shelly call I now financial results. turn review to the

Shelly Guyer

I'm based you, stock quarter, acquired Sean. present financials, assets, the P&L combination items expense, this acquisition to enhance of a numbers charges income little and intangible on going think of I will by from comp, acquisition investor’s Thank because amortization related related tax affected line the which differently our post benefit. most are understanding

at slide included provided XX today's a on have the in deck to reconciliation detailed We press Pages much through XX. release of both end and non-GAAP more tables our earnings

throughout I results GAAP non-GAAP. and discussion and the the will both refer my quarterly of to annual the

to Volume business. is slide reflects reconciliations the best the which and release deck. measure. We non-GAAP of in non-GAAP remains a provide press the which metric, Investors provided encouraged also review cash the health the in burn, are our

pleased the XXX,XXX accessioning We XXX,XXX samples quarter. approximately volume from to including XX% previous in more the in are growth samples than fourth nearly year XXXX, in report

number in of tests are period. accrue important our Billable that reports on we given the based revenue billable the

growth we the and across the approximately continued our in growth. the year-over-year in in approximately XXXX, increase volume Volume XXX,XXX with was partners, reported biopharma also all quarter. significant the fourth strong During Spark Detect, were programs The Seizure XXX,XXX and segments. program, contributors volume including of billable Behind

continue our expect our to key to play in We achieving programs pharma a targets. XXXX role

has our has quarter volumes. fourth traditionally we that been strongest first traditionally experienced the Recall and The our lowest. been our quarter seasonality quarter in

the volume mix affect seasonality, quarter in customer be new that may our first still we terms quarter will growth. magnitude slowest the of our While expect of

The between a which the accessioned of a and quarter, first accessioned our around consistent relationship in X%. affects billable Seasonality volume larger XX%. volume difference was X% quarterly and range basis, we is annual between gap billable anticipate to volumes. the historical in also with and On X%, our XXXX between accessioned billable historically

leading indicator While revenue. success next the key is the of is volume, our indicator

XXXX, the $XXX.X of additional having increase revenue January. fourth certain payments a of $XX.X XXXX, recognized million $X.X revenue We despite million revenue slightly notch Medicare XX% generated in We related comparator. Recall pre-announced quarter, in year-over-year in we in difficult the exceeding to this strong million including for early we that tests.

amount, XX% Excluding increased our revenue year-over-year. this by

under XX% over XX% from institutions, and XXXX, third-party patients. and from payers came revenue In just pharma partners of our

and party improvement by and Third billing in $XXX contracts an increased from in our with del/dup the under discussion our we year-over-year, down in processes. revenue when Medicare XXXX or expected our X% excluding in primarily approximately XXXX, XXXX XXXX, $XXX due payer menu trends of previous payments. of ASP steady tests Consistent an to in collections realized $XXX increase ASP in

revenues. seasonally The a XXXX, billable first our collections, of revenue in the volume and payer as along Remember revenue which and are primarily greater well impact In trend will products cash lower due quarter, we gap of guidelines, with the resetting as rates, changes, yields pickups affects see around better-than-expected to under ASPs that bounce in may driven revenue the subsequently ASP recognition mix bit. PAMA revenue. to accessioned volume and too. now growth by early lower first year quarter seasonality

which our costs tied Keep to is relate and on of over year COGS. impact we to XXXX, representing in fourth $XXX decreased in decrease with a these in this year, are intangibles $XXX average a sample COGS an In $XXX, year. in the activities. COGS our COGS decrease X% non-GAAP a also amortization our of the accessions per is more representing quarter, we average from year per comparable exclude costs XXXX, XX% year, mind XXXX cost acquisition that margin for When basis, as to sample an over portion of will gross

to volume and margin further will costs we additional around new with features or the reduced at do as we interpretation through to we continue COGS introduction we down the balance we believe content expect general, medical that per mark automation costs in related XX% gross In COGS. And fluctuate reductions, will from driving benefit of invest intend and improvements again the sample.

profit neared the key We $XXX We quarter saw fourth the operating and the gross near margin XXXX, in the success for $XX.X margin our model term In sustained significant our The of long financial the year for representing is of a our In In was term, reported fourth of is profit gross our On profit. quarter, XX% target previous key basis, for XX% the fourth was from we stated increase growth term the measure indicator gross the and million gross the XX% generate non-GAAP for XX% quarter. with long working. XXXX, margin gross cash a nearly is in to a business year. million ability gross XX%. year. increase flows. positive that

Moving to operating expense.

the the for year, $XXX.X quarter us market, Total enabling we expense, advantage volume, significant and is $XXX.X revenue compared of to our fourth cost during $XXX.X We falling the million in which us. XXXX, market internally continue discussed million. our was with Operating investments expand expense was intention the of XXXX. to the scale in operating several our to spend we into invest address ramp opportunity to million year areas. new XXXX, which before our Early continue excludes business, to take make to in for did full opportunities

volume channel, facilitate launched and First, advertising we to branding sales support product to headcount to increase June. our our and expansion direct begin and marketing, in launches which to

focused and to And the administrative growth research our and development on the support customer business, improving and content third, expansion, reducing Second, business. experience general of scaling COGS.

non-GAAP non-GAAP acquisition expense, was million base to in move was eliminates incurred related and comparison also post $XX.X the version combination more tangible indicative the and which spend quarter. in operating of is the assets, amortization The fourth XXXX acquisition based related non-GAAP The XXXX, makes and business, for stock operating expense. comp with the expense million of which of view our easier. Let's $XXX.X

fourth non-GAAP was related million compensation the stock the based quarter. XXXX, $XX.X measure in which of Bio million in of eliminates in Singular $XX.X to This acquisition

$XX.X had also million was in acquisition which assets post million XXXX, combination operating an and recorded tangible expense quarter. the and amortization in as fourth $X.X related expense of We in

year net XXXX loss full million share. net and quarter $XX.X XXXX, share for per or fourth million, of the loss or $X.XX $X.XX Our net was for $XXX per the loss

Singular growth. acquisitions. costs important is most in of an content is will expands for and of provided. flywheel our and terms drives our associated customer tax excludes improves acquisitions on advancing million seen What benefit Please Bio dramatically customer as assessment. $XX.X what Jungla Genetics with model, Non-GAAP refer did experience our income our the business improves each reconciliations of experience to mission our traffic. NIPS reduce Clear and and these

Moving was excluded, related with million various acquisition-related in ago. cash, in the a and increase to totaled the cash, fourth position. XXXX $XX.X million XXXX, $XXX line When quarter. are and cash annual cash in cash $XX.X equivalents $XXX.X cash At expenses, December fourth XX, expenses marketable what million, XXXX, approximately Cash was $XXX.X year burn $XXX financing cash quarter. million burn including the million equivalents, securities restricted would've in restricted been and Net indicated for cash million. various our and and including financing in we acquisition

investment then Looking last follow forward quarters, year's in cadence have increase to investments. we first burn $XXX that down lower marketing reap two of reflecting controlled the anticipate and will Medicare in to would the XX%. and higher rates of our We a Collections decrease back cash early from year in will as anticipate benefits as will million. XXXX’s selling and these burn half deliberate year in XXXX's R&D, another we a in XXXX the investment, be reset

also continued assess and we throughout We anticipate rationalization acquisitions XXXX. to industry of will continue our

call over back Sean. turn I will the to now

Sean George

you, Shelly. Thank

improve believe and lower more customers’ we bases, market our from we expand to will our for information genetic genetic market the incumbents continue global take As share continue experience, of expand our to menu content we importantly, dramatically. cost but

untold aren't risk XX% whether carrier that ovarian being millions their beginning, or of testing with during that if with currently variance is women Indeed, from the more who know they're don't and our their XX% it disease with the cancer than XX getting the a done for who and information, cardiovascular high first at are of families. have year but that all cancer million they for view just hereditary still breast the offered the is genetic threatening of that them, serious this could a and benefit screen prostate health one told women is test trimester, health men every or it's inherited

working, as With a operator one grow over than of continue of the confident that, our will ever the call that exciting we that We transformation and lean uniquely of to poised I industries that dynamic turn genetics more the runaway today. model most and is to now the the healthcare winner in will Q&A. are sectors for we

Operator

[Operator Instructions] Our Schenkel Doug question is with from first Cowen.

Your line open. is

Unidentified Analyst

Thanks on is This [Sabu] for for Schenkel. my Doug taking questions.

are a so sales reorder and to And percent? were what you do For example, you philosophy, up. three in if would forth? What increase so tell your us x Are have productivity key So cross-selling follow by guidance metrics I on XXXX your you rate expect baking the rates? be? any force to

Sean George

characterize has the that kind of evolved is guidance, the take think dynamics industry way I overtime, course to simply of exists which the today. our of to XXXX

Our the addition sales over XXX to customer current basically kind force into of or gets around up bigger visibility year of sales more into productivity the assuming happens you offs our some team reps accounts. as drop in numbers that modest base, year, move sales the to

will We direct We're growth screening. a more taking in with coming our we customer our some We are any guidance. testing could not those we an or in next for of there. of historically impact testing across genetic not lot disease there a growth from that do specialists and specifically not health, a reproductive but of, new or segments are all We where three expect into that. into start of whole one, our ordering have that channel. many And we baked that guidance, do do don't, really the on, guidance see order anticipate category in our a sure year which screening large turn from both anticipate testing. certainly, areas much we launching our two years we number while diagnostic There's in see

a year assuming this from action of either. aren't We clinicians lot those

and new kind So and know that for the additional accounts we’re that I see, year. we think the are market the on calling a of with, -- that that's we of commercial it's commercial engaged we're top current assets add what

been revenue have just reimbursement. slow the side, party have improvement And do in an a steady sorry on assumed third we we and as every quarter,

Unidentified Analyst

you in reproductive And lower for made so genetics progress And in called these accrual in the media as relatedly, so moving any of homes? well? headwinds business headwinds a your that as NIPT out key on reason can their revenue provide color seen health guidance. materialized you’ve far Have you in

Sean George

lower get in the we're for with a closely get latter, start and NIPS which are cost structure. who those house, still to track offering that on following means we'll So to better the reimbursement both

still the year. call call call it -- to we're in So early we'll it excited post-haste. pulling just We'll be out it in

progress So that. track of making there on we're

where the probably to think very back. difference be step So worth This a a really question, is models taking conversation. business in starts the the I center important other of it's

indeed and for four don't are, been is talk we five in after coming the offer of to activity negotiating within We actually years I We've are have a pricing accrual network the price starting value. commercial headwinds payers are move years payers finally leading headwinds, are now. them, as price of would leaders, about to

have the in like than in our that almost because So years we is dynamic XXX we quarterly, in largest see collections million stable now, now. payers as our that income revenue, the have again, primarily for and and the revenue way know five play going every now lot slightly -- price of we been us steady I why mentioned network not that's going see across just in machinery, in quarter improving we on that space. for leading lives that's menu And that, we continue reimbursed across billing is can with far fact, and our a to as more don't but see our improvement our other again, as and recognition

Shelly Guyer

The the is be only filed under filed would recognition. our is out do XX-K, collections. are in thing other out from We But by early we we what time needs it the March. break break I add will is what always be to revenue within that which additional around added for do accruing that additional

order to for. what we it's year $X which And have on about accrue so, million, had the collected of in anticipated. we've able been that is added what this been accrued the over and we've amount conservative we And

in positive as those XXXX, overtime that and we revenue the of that on number better about and estimating business. total our collection from that still our that's a And decrease perspective of think we're rates. will we're better So X% getting percentage

Unidentified Analyst

Got it.

Unidentified Company Representative

a addendum has QX maybe, for portion Medicare last the like hit for case you just it And just Medicare. year. an want up, that net reminder in is everybody doesn't to the just come that reduction, XX% to

Operator

And question Morgan. with that Tycho your comes next from JP Peterson

is open. line Your

Tycho Peterson

I'll start front. with the a payer couple on

the mentioned press in for could that you genome you of on to testing what breast incremental and release the ovarian. early-stage terms volume just CMS guys? You benefits in talk mean about, MCD expanding Can

Sean George

in the of Lee market. have any on size potential the We’ll comment changes

I always I think think could that and the of see think short, that I'll may action. in not, view in not means it's comment on I certain as changes that --we're kind we caveat about everything what mean same. wording in let it the potentially But the actually we what what with Lee

Lee Bendekgey

main three have interpretation by have language go we years on that the concerns really MCD at folks MCDs to the CMS evolved. this and as couple were of There So has as I the if focused evolved. the back, last saga think we

and being back one to coverage that going first was only to was stage cancer late was patients. be concern limited a pulled The

The coverage have into coverage to third its condition have comprehensive which way review getting testing the the Medicare testing in unnecessary that a second local discretion MCD, would would Medicare becomes that And the as process provide was one quality physicians, more FDA duplicative preventing and eliminate available. the a local implied that reimbursement. patients some higher be to from the precluded would it of the was would made of parallel MCD language under of which contractors including or requirement interest have the

have and degradation coverage. from been none we the those really of of repeat expansion worried three then ago. prevent where erosion of provision, ever perhaps proposed. represent their satisfaction started All were in to luckily community, don't, or They the thoughtfully and effect, fact just they an just And things the And don't in from exception the with testing -- when and of did listened about CMS the at they all carefully right complete thing. MCD to took that addressed we our the to we they two response the we of years folks credit this thought really are feedback were

Tycho Peterson

theme United Sigma And network. remind there status? Can us payers what is you around your in then preferred And payer additional just you're with and now? are just provider to sticking coverage with talking preferred payment then rate

Lee Bendekgey

way real everything amongst again, parties now's is of growing to more there I but that I say on about third think interested idea rapidly. mean want So could takes savings by line think this there's now very mean, -- while, the are item that a in status really don't we’re a what in party multiple that reimbursement definitely payers is time preferred because I talking others. I that to

from conversations patients to those even populations, whole all through coverage check-in, preconception conversations. Women of start from pediatric now lead kind of risk interestingly age the And with for reproductive high to the finish. of that broader groups way more cancer of the are

I'm the So and where having outcomes actually improve yes, years. be will exciting assume costs assuming the long place happening and we lab lower information thought in like conversations go. we’ll, prefer -- of certainly in payers a will a whole said, get for the would for beginning In feature put network this while to we more it but that even populations. take of But couple put next would networks I run,

right, XXX the stable, party and largest was the, me oh, pricing. ask there the $X,XXX the the that's payers been around pricing pretty for -- or price of of question, discussions million depending lives size Speakers] these contract [Multiple the slightly I a Again, last the has third forgot pricing, enter just them. about of you second the our under where on payers, where which we of

Tycho Peterson

initiated volume an volume since And then And give you just us generated? patient somatic any then is What update a time pricing percentages can DTC subscription has update on it model? separately, launch How launch? your traction testing line? much just on on

Lee Bendekgey

So not just large expected, a quickly really basically not or is traction the DTC as which

amount. we we it. material I of lot a mean, are looking for good know a there information. The that of There could people. this know lot people are people lot news that is of use there a

of We we amount that working I expectations all. a a to with we channel, really driving And this clinicians we but volume. at that generate dial to and as be now. in years not are going couple very traffic direct them, that on fair able firm marketing out we of in they're large years, take amount the But next some both five our of expectation are what conversion year sometime patients today mentioned, three and is significant care not the have the guide and the expect to who we'll interest we're majority have in

fairly where that It the it drive of volumes. a think to earlier, had we kind is large hit if however to thing potential were

working keep it. We'll So keep we'll posted. everybody on

assumed is get somatic timing. on it or way partnerships some, For larger for And year The this can year. will line. contribute half and we this early, the pickup assuming one, be be at just we're the still get now, somatic, might minimal if I of out year revenue the we two exact track we're get probably accession we're in it not a this going particularly right least half this year. by to it depending would some contribution it’s But nothing still on again on earlier. backhalf, -- trying out say to

Operator

from comes Leerink. next Your Souda with Puneet question SVB

line Your open. is

Puneet Souda

First question on NIPS.

to pricing, wanted of the of much importantly, resonating the reimbursed how is growth the in payers? from of in volume business view the from a terms pricing, market? sort coming that versus Just how is get currently in and traction more $XX And getting the

Sean George

So pick business in just pregnancies globe reproductive grow, expect now. sheer the the everything. general, ahead up We to rest the XX in opportunity, to the million reproductive the I'd years say of serving the continues our size here growth come, slightly to do around economies of of next year the right and we're again and given

as expectations we a right think So now. hoped. and great to we as ran carrier in again, well with good we place almost, of I Last as through testing associated the do our sitting it had did pleased for NIPS it. we and Obviously, kind year, we we're and screening wanted have year, but more we’re

it. and happy it in picture, we of mentioned and and it invested bringing as basis for our do is by exact dramatically NIPS -- launching what we the the cost plus we important carrier investing out the house in is would see that carrier. we acquisition Bio really of is we reproductive only, that way further that Singular For rate, is we're what But, whole reiterate don't really so piece NIPS only, in the ultimately of lowering NIPS having a break kind indeed offering exactly what

think health years the again, currently and said point. the much next there picture think few I chunk better we we've -- NIPS know, of can we million reproductive at that's they And in XX really them serve year than was that are. pregnancies a So this you significant

carrier versus of do price we've in probably what risk of We pay develops writing put years will be the track. the we're longer have a screening. important of patient recently very right. and and we've writing to think why what kind OBs and lot the guidance we lot where of dealing don't off question our of extraordinarily is think pretty of we that in, been policy ability more can to we moving of fact the the will just be, players exactly. the take risk have for market in with multiple not really to approach we mix. that as we think We've time might we're there's that believe there be pay have the NIPS. price, put lot a that typical in tend and OBs and a we into even the a that pretty bring By patient insurance build I that patient it's I average for A pricing out bill, got except in even a again, is surprises and right building expected out the What bills. the billing NIPS The both of on ACOG even kind coming women the in can say which On $XX don't in that pocket on virtue seems is and of would has high thousands seen come. the high the this keep straightforward to future just told taken again the clear, we get space dollars obviously taken

Puneet Souda

Shelly, add if plans on don't QX the to you into are sales for that. means also the that in is for a pointed I And the if areas rank and know if what what remind growing, Could and get rate a us you hoping Burn view additional you priorities that view here? maybe I what investment? force where order year. sales you the you give your out. could year for as the could provide spend was force currently is on the spend of

Shelly Guyer

So I that part? and why jump onto then go latter first let and Katherine answer part the don’t I'll

Katherine Stueland

growth this XXX and able the testing so year, early internationally. money last looking sales to we're the end average U. and at about towards S year, have We both of be to cover

percentage the same what and in I size force as sales earlier have increasing on for. we So looking commented that's, Sean productivity prior. the that's about year we're force think sales It's

Shelly Guyer

of us, And quarter. the priorities back you'll on hit my that business, enhance type then R&D, Jungla don’t of some really like million that I went the to things basically work instance, was some help if things like they out COGS we're rose then some to I for those present of our and when for X to scaling, the for some you through the driving customer customers. the add And web why experience, the based able such, script, like I had see non-GAAP, comp stock down, acquisitions that that access everything of and and the in things you on new automation, in the last product of acquisitions that

very and of channel extra is goes was to so to talked focus running what selling like as get what heads something during And ours. brand terms up a about marketing branding out it advertising is you spend able that the and million quarter. and And of has When some at but and increase look not in only awareness, some of and for $X the strip in costs the that the those being that's also of last well such. still you much acquisitions new of as direct marketing year, Sean the and

are the some of as as experience those in the And that's and so well acquisitions key genetics things, clear customer the

urologist physician enhance and a be any our a use offering hand, for in and so patient our the scalability, the new else. of ease the two, to hand breadth the and product customer, work able marketing physician, type that's like or And R&D a or of or a sales those offering, of somebody whether to the

importantly tried I some why through focus think we of And burn looked those to make versus So those so at. decision. buy that also will some important the to to but were us, walk are of add us, we build acquisition we the the sort

very the accelerate And Clear we've as has that those be of to can company and great so at technology able we us these dollars a opposed up ourselves. to that decided trying some you project it like to can look bottom important R&D or build Jungla that from a some for buy by to

that own why we're we investments. these evaluate for to priorities rapidly on to see And some going think get of types the are those those we about. each So of return how their investments that's

Puneet Souda

how the you to your Sean, if And and does germline model the -- you've driven. that pricing it rationalization at the has and could of in if business back look testing could space landscape and evolved speak step I

you where term you expansion to you Thank term priorities look not the long if [Technical could to where Given in on a you. elaborate on overall you ultimately where you be, priorities at gather terms priorities, stand today data and changes you long might want of those today menu or the any want view in be long or areas and term Difficulty]?

Sean George

quarter. Our view we do think, and getting industry it's every more dynamic of the

picking is the So speed. up rationalization

a But the application take of chosen I think and are developments to area all. industry technology there our lot its kind to the wise. hasn't exciting view that really of potential and it changed of in and we've approach at

our strategic of a content as on We more growth. part are still and outlook on key working more adding

the the getting kind of expect is has better of and and past We in the childrens serve year. pediatric to and would centers that, for example a kind out to that more continues sure been I really menu same hospitals for rounding this be mentioned focus of major have

into both as continuing of in for post move offering, of the downstream for likely out the more to evolution at to and monitoring cancer information course content look the decision and cancer and recurrence but then identifying leader of being stratifying just add now itself. characterizing risk not then way Rounding by risk individuals our it and then more therapeutic oncology we to particularly

areas are interest is that fits is that particular with about well talked is we we've think an and think area be our that always that built. pharmacogenomics those a course that in as that's something continued So wheelhouse look we growing we've the something platform to to, right integrated as we again, and to of payers providers,

working that's and I we've it's again on. deal no And interested that in still think surprise we're we with that mentioned something before

of and no to been discussing the dramatic hope with year platform. we've the so or of the the real next the that content usual we kind add to suspects bring the outlook, change kind to of So no change really in to some expansion

Operator

DeGeeter Oppenheimer. from is question Kevin with next Your

Your line open. is

Kevin DeGeeter

it that that feel just on the preferred questions think a volume of experience about follow of is shaping And with like what's early be we as about to United’s to market? near-term? your can regard suppose impact the lab want I XXXX, comment on growth in earlier take? dynamics XXXX network, lever driving up still to the and in volume lab and a more material preferred you could impact network terms be in put been modest just I Or or your on up the has

Sean George

we succinctly I total percent this by the large of question think, haven't baked And know, really guides. the any saying expectations United really into States live. I modest is year's you can the certainly

that's space network. that So, can benefits obvious still table. being that the the we side on some With is of said, what are pretty absolutely that fragmented that, I a of say preferred in think there

to is as and important. lot a is the mechanics of very which items. our virtue is the smoother the clinician us the much one kind network lot much kind billing our space that also versus and It being of Certainly are much, number menu our number order of which important, very of of in reimbursement by of they're much on on end, through in peers of easier on a side, from

So those all great. are

of probably inconsequential just you bit would a virtue volume kind we to from by I if versus think there still But commercializing. came very it’s that growth think difficult I a is that step of put offer, how on back. much number take the little out

business genetics and is they and that is early payers going preferred reimbursement doesn't. an their of is few has series have as are definitely the think they who example if overall over on it the very the years first that The bigger the dynamic becoming important is paying are ever from they more that network, attention, what I the And and do. we picture consider is the believe here, the to impact to probably one moves space in access of moves a next

that's So to come back to to But of of real on this step view, impact It's that's leave in landscape. would kind think we what it material it. on evolution put view is one's I'll and of time. this think this the actually a certainly this taking a I any I pretty at our point hard important where expect definitive

Kevin DeGeeter

does any that, the that amount And as DTC around guess the to opportunities genetic over very about, been generation M&A companies, you create this build continues potentially on there's active? think different your of level interest your the and for perspective any market that channel testing fair being part location the a or follow or two. is any publicity tangential first of out area up the an a plans have downsizing would direct of an next year direct really recognizing issue plays that accelerates, or of I channel a And in you from some

Sean George

So of does really huge raised I kind been is those had lot genetics off, it why that’s spins typically product think of honestly awareness from company has just kind but over per about on opine in interest, know DTC can't, don't right can't what I I decade. why. industry a if more of it what's is in seeing the marketing I on tailed of interest our larger the a certainly comparison to been the think tailed a basis. off know getting All has past the order or It's competitive. about there consumer on with we we players, there announcements lot much that going

a We been in created of really dollars a of awareness those that lift marketing general, there's We feel last genetics opportunity. an say can't decade. over as much. has massive result the general that think We

individuals of of do them interested the are in are and of market of satisfied with health not work, get. results mill show half super more the can the kind who that run tests will You than research they your most you buy those

our in overlap we and are benefit been but just customer very, discount that these individuals think the undiagnosed aware clientele. is diseases, so there. segment past. than who there's probably could focused individuals This be testing who nowhere medical very don't on. there's Again, active there and for channel drive kind of get probably core think opportunity I started pointing be some the different children for -- are we will for using So family, really have they The the where of worth rest know nor clinicians to who bandwidth the run that of have the But a companies clients, conversation to starting thinking not that's have very channel definitely that of with directs to our to focusing it. patient's same definitely channel grade kind back the an a exact genetics

And satisfactory, means. know was don't in maybe I really say just going we it to what

though, the value diagnostic can have for trying have on type negative and reach kind playing of think their and value assets. predictive this where very we predictive about we're table. -- with is M&A know screens customers We're positive people the can your best health. active much the screening We around DTC ahead the questions kind to is that So don't highly focused out working answer there's team of to with we more those maybe question the sure only area I this I'm tests

Shelly Guyer

to And going The brand. spent market years that's really medical start now menu strong the only help thing testing are ordering building And consumer the really in our testing. we that of and I we interestingly, succeed we to six broader ordered. would is a think more mainstream add is is, as breadth what seeing us being clinicians

Sean and cancer reproductive as diagnostic testing, health mentioned, screening, So there's cardiovascular there's testing. there's

genetics inform health well-positioned be to think the being we interest that the increasing So bring to and we're to to in able care decisions. serve long-term able

Operator

with Cohen Thalmann. question Your Ladenburg Jeffrey next is from

open. is line Your

Jeffrey Cohen

some and further side. could of as automation, it was more our the expand wondering the side on as for the analytics coming far you software from or comments previous if I time equipment is

Sean George

Automation is R&D. of acquired And think key definitely the it both in correct a and is cash side both component and or R&D side. equipment on we've our is both. software automation in So burn, the R&D own booked at to the it, OpEx about

customer the to improve same So the sales while I think we the both that important, experience of at yield both that short time to think lower and/or we have benefit cost continued marketing are have the is delivering advantage a answer to and the burden experience. room

of kind automation lab this an acquired wet point. provider haven't to we've So automation

I front with the that very on identify would for patients acquisition right of end by in unseen to think of of say, represents have automation which clear, there. big et cetera. expect and step, in triaging example solid the front move automation be it’s billing, pretty way of continue And the be now a We very customer tests about here, part I the the scheduling the getting it scheduling that I questions going to answer acquisition to do questions, follow key up, side, with we the and invest next type a continue genetic that customers and right over test great important, for invested that what ordering, in would then the more pretty Genetics counselor, clinicians, we of need years. scale end, years their the automation Clear to answer service our to on is to and quickly automated the on is a really Essentially example to into come. scale do,

Jeffrey Cohen

us sense both Are the Jungla, of they Clear or Genetics. tucked-in you a they And as complete well XXX% the this into could overall at integration as are give of business point?

Sean George

most completely, the within organization what love are integrated, of development integrated for and see. completely we few or more in kind new say efforts. development Clear teams answer technical we the those have efforts months get are the think companies short less. development part, of is still we Invitae respected of aspects to they're it software leading, that are I There of frankly platform the development integrated. I'd principles the that fully our some a the But The

of have already variance number able uncertain of very been large significance. We a reclassify to

variants unambiguously, today approach And a significance we that the is that completely now with uncertain at of working as start Jungla to with derivative platform, as stand now say from resolving can we we we these and integrated speak. finish, best and

part, more are actually molecular have for other that on to the will that that the take excited team evolution and are we're Jungla development that most initial There there integrated. of that's the much see they But are pretty the returns time that working come. platform been aspects So great. on for and

specialists I excited of these to occlusion we genetic what of for have do integrated. it's outs the practice. in are a kind daily their of deal are testing lot we about lot that not a can time For who ins of particularly And bandwidth medics mentioned or with effectively do, and

in from looks the is track. the And I very a from that as and perspective, then closer. every short complete we and I product think timeline on integrated coming we'll mentioned well there perspective a get But and development few months weeks closer are

Jeffrey Cohen

about you share? can then there the from cardiovascular update talk information Could disease starting? there you Thanks. me. lastly And any Is and

Sean George

We're just So the that. starting I -- what the -- --. with that's can right by -- I Watch would think say, talk tell Bob about Apple can study, I just

collecting -- So [indiscernible] into data alongside of further there's we're loaded if don't any that information way I by longitudinal with it Watch the genetic off -- [Multiple getting Apple and getting kicking know just Bob collaboration. that Speakers]��

Bob Nussbaum

able to and very forward to it the analyze being we're It's data comes early looking along… when

Sean George

days early for …so that.

Operator

Company. question next Benchmark with is Your Bruce from Jackson

open. is line Your

Bruce Jackson

of that exiting rate from be where last revenue markets. mentioned international you Do XXXX? a total earlier have be, year your about of So might XX% came might that where you you sense

Sean George

because makes of direct -- and revenue, the payers, all so -- Yes, in third slightly pay just on -- there's the party bill XX% of volume patient -- a assuming is aren’t some pricing there -- little it's clarification is year. lower international guides, this in price more is revenue. in our of said, volume percent our where lower With that exiting same the are we about it’s XX% to compressed, markets a so

shipping issues investing in we're our of more actually our activity, in the -- and order have dozen Handful business we're encountered -- really both physical increasing been whole commercial so development are in the support. a uniting that and logistics hoping having generated lot business of -- adding of that that commercial start way with And out that plant XX% a take to relatively in to volume of associates around historically international ex-U. small we're We country our force. globe. S. half has by literally and or modest a dozen we

part, year we're been depends interest. market the inbound implant that like, a untapped lot opportunity. happen to confident rapidly of is Now for answering can which years how with the a this We're quickly but will we've come. that very get the that confident again selling that large we in look cycles on property start deployed growing Could that that most

really we we're like of I haven't and haven't more anything said, So for XXXX. XX% we volume in excited But baked optimistic. than our about -- we’re

Bruce Jackson

country orders the primarily And that mechanism? Or GDP? countries So I And private there component it you're then that? payment could. from? is it follow-up healthcare pay? mix question, a is mirror of is getting insurance that if any the to larger just the Does Is -- what the is then it

Sean George

by the the see Middle volume on to weighted follow are Northern Israel, single how East, Yes, just to so, answer And lot the for individuals so regulations, largely specific UK, result genetic is, are state think, this just payers there, Europe, is not no. first GDP. have it sample is, and Latin a whereas set does I examples. a it's America, for more also France of and which tend relatively all launch first institutes GDP. the England, it to to actually short and and -- that's largely, that's up of question totally not testing, Pacific, is, -- It of we pay Asia difficult for

pay ex-U.S of think kind we bill accepting bill, institutional are as these of like a for don't mix extra it hospitals. of, are to supplementary large think in institutional genetic really But about U.S. payment that is of hospitals, way then run privately is primarily mix think testing. this pays a oftentimes of in-health or it, insurance who large some here -- have the And The and patient also or academic clinicians, there the things

funds, those, of pools those are, health are for testing. being for insurance -- being countries, then insurance, the the those these government, a sign in additional in what's and pay used and to So up funded, sometimes program clinic many there's can what payer single are insurance people

Operator

question is next with Laboratories. Capital Market Ophir your And from Gottlieb

Your line is open.

Ophir Gottlieb

Hey, for guys. I don't questions. you Thanks mind. taking the two, have

is cash providing to than XXXX be, guidance going excluding acquisition XXXX? for, various simply little costs, formal for that and bit the more financing You or are burn

Sean George

No, yeah.

on leaving We now. are not, That it, formal in providing I guidance we're think.

see course of covered which detail As a both and that by a investments and the just is is -- before. to This of that is of we've us front, investment is that primarily this be it R&D and or it's think everything -- commercial will little year on and be we view. in a our a going build continue more, is what extending proxy, more kind most of in year win and take in it, put which we to case, we M&A continue commercial for R&D. in can as opportunity We a leadership

stays, the helps commercial created think building, content that's are we're and suggesting We're Or our and us that reasons the that that partnerships. overtime in those advantage, which new formula pushing that our broadest, winning well the translates is price the, -- that winning of our that, model whether on translates highest quality pharma the is as cost is of -- this what think we now. best, on are at building all with why invest that primarily year business a operating an future, We working superior long-term, network, burn is this driving R&D, as EBITDA the that's that leverage, at year what, is do the investment forward the that, sales into Extending well. as cash the customer have and flows massive kind we we marketing, time we’ve experience. because it's then over globally, that and price, think really menu, at metrics but to single moving our position building targeted we're in customer sustainable toward and in financial We the as pharma, been landscape new and unassailable that, for types,

Shelly Guyer

people be in about, talked will about there the fourth so January quarter expenditure, ending number the note have were front as brought would, on those and February. of been and sales in and talked we I that of some, early And, they,

be quarter things so in become you're those a have customer these of, on the and things, you lot And those going we for able see products type, corrective, brought scale with to folks, R&D hit year that to fourth the terms quarter experience goals other costing first in will to, before they and of and content.

pay in higher always your so also the burn quarter we by And PMA have and also a -- reimbursement commissions decrease in have you you sessions. the first

-- beginning become are to that the wouldn't this the trending to R&D from is higher and we perspective, I be to as half get quarter more higher productive the year year second from the able beginning down And of those so surprised, people want the in is first you yield results sales of then efforts. year the the and and we thinking be and last

Ophir Gottlieb

this right fees, shipping have hours up understand is for doesn't I of you some now version go as two which that question, last And with course Difficulty] [Technical the it international business, to officials It that point is or $XXX hate. with international the at to of envy isn't completed [indiscernible]? removed you that extra year you're XX% this some forward case have moving that whenever

Sean George

there these you're, will, reducing much screen, of in I'm are down paying significantly right shipping that so idea. I ensure the size countries but is shipping exactly allow the is logistics, that cover the the we the of not as there'll for are as there almost be cost that's some -- institution the examples they in, shipping because test where are patient the idea markets idea. of the we by remove most that sure to mean, bill

right in You frankly that. reduce customs removing cost reasons said two purpose also of way that's with and in that's not are the issues that ex-U.S investment really friction, turnaround not help improve, physical of that primary I really which our think in the logistics and now held by the benefiting is was you like the improve dramatically out and the the infrastructure. our up getting time primary things and Those the but anybody, correct, the

Operator

Laura I'll This turn D'Angelo. conclude things to period. does the back And Q&A over

Laura D'Angelo

us to you soon with joining today. up We Thank at upcoming, you catching look, forward conferences. for

Operator

disconnect. this participation Ladies and does you and now today's your conclude calls conference gentlemen, may for you thank

Invitae (NVTAQ) 19 Feb 202019 Q4 Earnings call transcript